Holen Sie sich die Stockscreener-App
3.54
0.85%
0.03
Handel nachbörslich:
3.54
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics Raises $20 Million in Equity Financing - TipRanks
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Aug Intraday: Whats the beta of Aclaris Therapeutics Inc stock2026 Weekly Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
ACRS: Multiple late-stage immunology assets advance with funding secured through Q4 2028 - TradingView
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference - MarketBeat
Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles - StocksToTrade
Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com
Aclaris Therapeutics, Inc. 8-K SEC Filing Summary – Company Information & Details (March 9, 2026) - Minichart
Aclaris Therapeutics Raises Capital via Institutional Stock Sale - TipRanks
Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering - TradingView
Institutional investors buy 12.7M Aclaris (ACRS) shares for $39.8M - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Can Aclaris Therapeutics Inc. (8AT) stock hit consensus price targetsTrade Risk Assessment & Verified Short-Term Plans - Naître et grandir
Investment Recap: What is Aclaris Therapeutics Incs P E ratio telling usJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
Aclaris Reports 2025 Financial Results and Clinical Trial Updates - MyChesCo
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma - MyChesCo
[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference - marketscreener.com
Technical Analysis: Why is Aclaris Therapeutics Inc stock going upTrade Risk Assessment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline - Investing.com Canada
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates - Investing.com Australia
Aclaris: Q4 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (NASDAQ: ACRS) outlines deep immunology pipeline and 2025 losses - Stock Titan
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference - MarketBeat
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Aclaris Therapeutics (ACRS) narrows 2025 loss and details 2026 trial milestones - Stock Titan
Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Aclaris Therapeutics Reports Positive Interim Phase 1a Results for ATI-052 and Advances Pipeline with Upcoming Trials and IND Application - Quiver Quantitative
Mouse hair regrows 93% in Aclaris alopecia study, 2025 loss shrinks - Stock Titan
Aclaris: Fourth Quarter Financial Overview - Bitget
Aclaris starts phase 1b trial of ATI-052 in asthma patients - Investing.com Australia
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - The Manila Times
Aclaris tests experimental asthma antibody in new human trial - Stock Titan
Aclaris Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Market Rankings: Whats the beta of Seacoast Banking Corporation of Florida stockJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Will Aclaris Therapeutics Inc. stock recover faster than peersWeekly Market Report & Community Driven Trade Alerts - mfd.ru
Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris lines up February spotlight at major biotech investor conferences - MSN
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN
Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 - MarketBeat
Aclaris at Guggenheim Summit: Strategic Biotech Developments By Investing.com - Investing.com Nigeria
Aclaris at Guggenheim Summit: Strategic Biotech Developments - Investing.com
What’s the beta of Aclaris Therapeutics Inc. stock2025 Fundamental Recap & Long-Term Investment Growth Plans - mfd.ru
Atopic Dermatitis Market to hit $31.68 billion by 2033 | Major - openPR.com
How dovish Fed policy supports Aclaris Therapeutics Inc. (8AT) stockWeekly Volume Report & Long-Term Growth Stock Strategies - mfd.ru
February 2026's Promising Penny Stocks To Consider - Yahoo Finance
Aclaris Lines Up February Spotlight at Major Biotech Investor Conferences - MyChesCo
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):